IDH1 and glioma: Shao et al identified IDH1 mutation in EVs from serum using a relatively new magnetic nanosensor technology, and Chen et al have identified IDH1 mutation in EVs from CSF of patients with gliomas using novel techniques such as BEAMing (beads, emulsion, amplification, magnetics) PCR and droplet digital PCR (ddPCR).71,72 Hence, EVs not only can offer noninvasive early indication of tumor progression or recurrence but can also aid in the detection of IDH1 and EGFRvIII mutations.